Protara Therapeutics, Inc. (TARA)

Protara Therapeutics' stock experienced a surge followed by profit-taking. A $75 million public offering caused the stock to fall due to dilution concerns, despite extending the cash runway into 2028. Positive clinical trial data for TARA-002 in pediatric lymphatic malformations and BCG-naïve NMIBC patients led to positive market reactions. TARA-002 received FDA Breakthrough Therapy and Fast Track designations. Insider share withholdings and the company's addition to the Russell 3000® Index also influenced stock performance.

Protara Therapeutics does not experience traditional demand seasonality as a clinical-stage biopharmaceutical company. Its activities are centered on research, development, and clinical trials, and demand for future products will be driven by medical need and market access rather than seasonal fluctuations.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing therapies for cancer and rare diseases. Their pipeline includes TARA-002, a cell-based therapy in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral nutrition.

Protara Therapeutics is headquartered in New York, NY, United States. The company plans to expand its THRIVE-3 registrational trial for IV Choline Chloride into European Union markets, indicating a broader international reach for its clinical development activities.

Protara Therapeutics' brand reputation has been positively influenced by positive clinical data from trials for TARA-002 and regulatory recognition from the FDA. Public offerings have led to concerns about dilution, which may temporarily affect investor sentiment. The company's mission and experienced management team contribute to a reputation focused on patient-centricity and scientific innovation.

Protara Therapeutics has significant institutional ownership, with over 71% of shares held by institutional investors as of the third quarter of 2025. Major institutional shareholders include Janus Henderson Group Plc, Vanguard Group Inc, and BlackRock, Inc. Individual investors hold around 11% of the stock, while insiders own approximately 2.79%.